2
|
Li Y, Li HM, Li ZC, Yang M, Xie RF, Ye ZH, Gao X, Zhou X. Ingredients, Anti-Liver Cancer Effects and the Possible Mechanism of DWYG Formula Based on Network Prediction. Onco Targets Ther 2020; 13:4213-4227. [PMID: 32523357 PMCID: PMC7237122 DOI: 10.2147/ott.s238901] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/16/2019] [Accepted: 03/18/2020] [Indexed: 11/23/2022] Open
Abstract
Background Hepatitis virus infection plays a critical role in liver cancer initiation and development; so the purpose of this study was to investigate the anti-liver cancer effects of DiWuYangGan (DWYG) which was effective for hepatitis. Methods Network predictions were performed. Next, several tests, including HPLC, Caco-2 absorption models, MMT, protein chip, Western blotting and H22-tumor-bearing mouse, were carried out to investigate the effects and possible mechanism of DWYG. Results Network results showed DWYG might be involved in some processes such as STAT cascade. Some target genes may correspondingly participate in these procedures, such as IL-6, CASP3, AKT1, PPAR, and TP53. Diseases associated with DWYG formula may be liver cancer and hepatitis. Potential active compounds might be CUR and ISO. Chemical analysis results showed that ingredients in the formula, including DEO, SCHB, SOLA, SOLB, SCHA, LIQ, ISO, POT, and CHL, could be determined, indicating that DWYG samples for the following experiments were controllable and consistent. Caco-2 absorption of ingredients in DWYG, including DEO, SCHB, SOLA, SOLB, and LIQ, worked very well. In vitro experiment results showed that DWYG could inhibit the growth of cell lines and its effective ingredients might be SCHB, SOLB, SINA, SINB, SOLB, CUR, DEM, BIS, and GER. Further protein results showed that DWYG could upregulate the expressions of some proteins, including ERK1/2, AKT Ser473, BAD Ser112, PRAS40, Thr246, P38, Gsk-3β, and Ser9. In vivo experiment results showed that DWYG could shrink tumor size, recover ALT and AST, and decrease IL-6 levels. Their possible mechanism might be through the JAK/STAT3 pathway. Conclusion Besides the known pharmacological function of anti-hepatitis, DWYG extract expressed anti-liver cancer effects and the results were consistent partly with network predictions. ![]()
Point your SmartPhone at the code above. If you have a QR code reader the video abstract will appear. Or use: https://youtu.be/bDMyKJpiig0
Collapse
Affiliation(s)
- Yao Li
- Pharmacy, Longhua Hospital Shanghai University of Traditional Chinese Medicine, Shanghai 200032, People's Republic of China
| | - Han-Min Li
- Hepatology, Hubei Provincial Hospital of Traditional Chinese Medicine, Wuhan 430061, People's Republic of China
| | - Zhi-Cheng Li
- Surgery, Shanghai Pu Dong Hospital, Shanghai 201300, People's Republic of China
| | - Ming Yang
- Pharmacy, Longhua Hospital Shanghai University of Traditional Chinese Medicine, Shanghai 200032, People's Republic of China
| | - Rui-Fang Xie
- Pharmacy, Longhua Hospital Shanghai University of Traditional Chinese Medicine, Shanghai 200032, People's Republic of China
| | - Zhi Hua Ye
- Hepatology, Hubei Provincial Hospital of Traditional Chinese Medicine, Wuhan 430061, People's Republic of China
| | - Xiang Gao
- Hepatology, Hubei Provincial Hospital of Traditional Chinese Medicine, Wuhan 430061, People's Republic of China
| | - Xin Zhou
- Pharmacy, Longhua Hospital Shanghai University of Traditional Chinese Medicine, Shanghai 200032, People's Republic of China
| |
Collapse
|
3
|
Pla-Pagà L, Guirro M, Gual-Grau A, Gibert-Ramos A, Foguet-Romero E, Catalán Ú, Mayneris-Perxachs J, Canela N, Valls RM, Arola L, Solà R, Pedret A. Proteomic Analysis of Heart and Kidney Tissues in Healthy and Metabolic Syndrome Rats after Hesperidin Supplementation. Mol Nutr Food Res 2020; 64:e1901063. [PMID: 32281714 DOI: 10.1002/mnfr.201901063] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/10/2019] [Revised: 01/29/2020] [Indexed: 01/17/2023]
Abstract
SCOPE Proteomics has provided new strategies to elucidate the mechanistic action of hesperidin, a flavonoid present in citrus fruits. Thus, the aim of the present study is to determine the effects of hesperidin supplementation (HS) on the proteomic profiles of heart and kidney tissue samples from healthy and metabolic syndrome (MS) rats. METHODS AND RESULTS 24 Sprague Dawley rats are randomized into four groups: healthy rats fed with a standard diet without HS, healthy rats administered with HS (100 mg kg-1 day-1 ), MS rats without HS, and MS rats administered with HS (100 mg kg-1 day-1 ) for eight weeks. Heart and kidney samples are obtained, and proteomic analysis is performed by mass spectrometry. Multivariate, univariate, and ingenuity pathways analyses are performed. Comparative and semiquantitative proteomic analyses of heart and kidney tissues reveal differential protein expression between MS rats with and without HS. The top diseases and functions implicated are related to the cardiovascular system, free radical scavenging, lipid metabolism, glucose metabolism, and renal and urological diseases. CONCLUSION This study is the first to demonstrate the protective capacity of hesperidin to change to the proteomic profiles in relation to different cardiovascular risk biomarkers in the heart and kidney tissues of MS rats.
Collapse
Affiliation(s)
- Laura Pla-Pagà
- Eurecat, Centre Tecnològic de Catalunya, Unitat de Nutrició i Salut, Av/ Universitat 1, Reus, 43204, Spain.,Universitat Rovira i Virgili, Facultat de Medicina i Ciències de la Salut, Functional Nutrition, Oxidation and Cardiovascular Disease Group (NFOC-SALUT), C/ Sant Llorenç 21, Reus, 43201, Spain
| | - Maria Guirro
- Nutrigenomics Research Group, Biochemistry and Biotechnology Department, Universitat Rovira i Virgili, C/ Marcel·lí Domingo 1, Tarragona, 43007, Spain.,Centre for Omic Sciences, Joint Unit Universitat Rovira i Virgili-EURECAT, Centre Tecnològic de Catalunya, Unique Scientific and Technical Infrastructures, Av/ Universitat 1, Reus, 43204, Spain
| | - Andreu Gual-Grau
- Nutrigenomics Research Group, Biochemistry and Biotechnology Department, Universitat Rovira i Virgili, C/ Marcel·lí Domingo 1, Tarragona, 43007, Spain
| | - Albert Gibert-Ramos
- Nutrigenomics Research Group, Biochemistry and Biotechnology Department, Universitat Rovira i Virgili, C/ Marcel·lí Domingo 1, Tarragona, 43007, Spain
| | - Elisabet Foguet-Romero
- Centre for Omic Sciences, Joint Unit Universitat Rovira i Virgili-EURECAT, Centre Tecnològic de Catalunya, Unique Scientific and Technical Infrastructures, Av/ Universitat 1, Reus, 43204, Spain
| | - Úrsula Catalán
- Universitat Rovira i Virgili, Facultat de Medicina i Ciències de la Salut, Functional Nutrition, Oxidation and Cardiovascular Disease Group (NFOC-SALUT), C/ Sant Llorenç 21, Reus, 43201, Spain.,Institut d'Investigació Sanitària Pere Virgili, Av/ Universitat 1, Reus, 43204, Spain
| | - Jordi Mayneris-Perxachs
- Centre for Omic Sciences, Joint Unit Universitat Rovira i Virgili-EURECAT, Centre Tecnològic de Catalunya, Unique Scientific and Technical Infrastructures, Av/ Universitat 1, Reus, 43204, Spain
| | - Nuria Canela
- Institut d'Investigació Sanitària Pere Virgili, Av/ Universitat 1, Reus, 43204, Spain
| | - Rosa M Valls
- Eurecat, Centre Tecnològic de Catalunya, Unitat de Nutrició i Salut, Av/ Universitat 1, Reus, 43204, Spain.,Universitat Rovira i Virgili, Facultat de Medicina i Ciències de la Salut, Functional Nutrition, Oxidation and Cardiovascular Disease Group (NFOC-SALUT), C/ Sant Llorenç 21, Reus, 43201, Spain
| | - Lluís Arola
- Eurecat, Centre Tecnològic de Catalunya, Unitat de Nutrició i Salut, Av/ Universitat 1, Reus, 43204, Spain.,Nutrigenomics Research Group, Biochemistry and Biotechnology Department, Universitat Rovira i Virgili, C/ Marcel·lí Domingo 1, Tarragona, 43007, Spain
| | - Rosa Solà
- Eurecat, Centre Tecnològic de Catalunya, Unitat de Nutrició i Salut, Av/ Universitat 1, Reus, 43204, Spain.,Universitat Rovira i Virgili, Facultat de Medicina i Ciències de la Salut, Functional Nutrition, Oxidation and Cardiovascular Disease Group (NFOC-SALUT), C/ Sant Llorenç 21, Reus, 43201, Spain.,Hospital Universitari Sant Joan, Av/ Doctor Josep Laporte 2, Reus, 43204, Spain
| | - Anna Pedret
- Eurecat, Centre Tecnològic de Catalunya, Unitat de Nutrició i Salut, Av/ Universitat 1, Reus, 43204, Spain.,Universitat Rovira i Virgili, Facultat de Medicina i Ciències de la Salut, Functional Nutrition, Oxidation and Cardiovascular Disease Group (NFOC-SALUT), C/ Sant Llorenç 21, Reus, 43201, Spain
| |
Collapse
|
4
|
Sirt1-ROS-TRAF6 Signaling-Induced Pyroptosis Contributes to Early Injury in Ischemic Mice. Neurosci Bull 2020; 36:845-859. [PMID: 32253651 DOI: 10.1007/s12264-020-00489-4] [Citation(s) in RCA: 18] [Impact Index Per Article: 4.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/24/2019] [Accepted: 10/04/2019] [Indexed: 01/01/2023] Open
Abstract
Stroke is an acute cerebro-vascular disease with high incidence and poor prognosis, most commonly ischemic in nature. In recent years, increasing attention has been paid to inflammatory reactions as symptoms of a stroke. However, the role of inflammation in stroke and its underlying mechanisms require exploration. In this study, we evaluated the inflammatory reactions induced by acute ischemia and found that pyroptosis occurred after acute ischemia both in vivo and in vitro, as determined by interleukin-1β, apoptosis-associated speck-like protein, and caspase-1. The early inflammation resulted in irreversible ischemic injury, indicating that it deserves thorough investigation. Meanwhile, acute ischemia decreased the Sirtuin 1 (Sirt1) protein levels, and increased the TRAF6 (TNF receptor associated factor 6) protein and reactive oxygen species (ROS) levels. In further exploration, both Sirt1 suppression and TRAF6 activation were found to contribute to this pyroptosis. Reduced Sirt1 levels were responsible for the production of ROS and increased TRAF6 protein levels after ischemic exposure. Moreover, N-acetyl-L-cysteine, an ROS scavenger, suppressed the TRAF6 accumulation induced by oxygen-glucose deprivation via suppression of ROS bursts. These phenomena indicate that Sirt1 is upstream of ROS, and ROS bursts result in increased TRAF6 levels. Further, the activation of Sirt1 during the period of ischemia reduced ischemia-induced injury after 72 h of reperfusion in mice with middle cerebral artery occlusion. In sum, these results indicate that pyroptosis-dependent machinery contributes to the neural injury during acute ischemia via the Sirt1-ROS-TRAF6 signaling pathway. We propose that inflammatory reactions occur soon after oxidative stress and are detrimental to neuronal survival; this provides a promising therapeutic target against ischemic injuries such as a stroke.
Collapse
|